

Presentation at Ausbiz Investor Connect Sessions

BRISBANE, AUSTRALIA, 12 February 2025: AnteoTech Ltd (ASX: ADO) is pleased to announce that it will be presenting at Ausbiz's virtual Investor Connect Sessions this afternoon.

The presentation, which is attached to this announcement, provides an overview of AnteoTech, and our platform technology, addressing global challenges, supporting the transition to renewable energy and democratising healthcare in growing markets. This event offers new and existing investors a valuable opportunity to gain insights into the Company's ongoing progress and market positioning.

A copy of the presentation is attached to this announcement and will be available on the Company's website following the event.

The event is free to attend. Please register with Ausbiz through their registration page [here >>](#)

This announcement has been authorised for release by the Company Secretary of AnteoTech Ltd.

- ENDS -

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech - (ASX:ADO)

AnteoTech is a revenue-stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo X™, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry. The portfolio includes a proprietary high silicon anode, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets; from global diagnostics companies to technology developers. The unique characteristics of AnteoBind™ provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates and Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to AnteoTech' business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.



Investor Connect Sessions

David Radford – CEO & MD



IMPORTANT NOTICE

SCOPE & LIMITATIONS

This Presentation has been prepared by AnteoTech Ltd (**AnteoTech** or the **Company**) (ASX.ADO). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States.

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

CREATING VALUE BY THE
ACCELERATED DEVELOPMENT
AND COMMERCIALISATION OF
SOCIETALLY BENEFICIAL
SOLUTIONS BY OUR
INNOVATIVE TECHNOLOGY
AND PASSIONATE TEAM

PLATFORM TECHNOLOGY DRIVING THE FUTURE

Proven technologies for the rapidly growing battery anode and life science diagnostics markets



Clean Energy Technology

Anteo X™

Anteo X™ is a **performance enhancing additive** enabling the move to high silicon containing anodes demonstrating **improved performance** in lithium-ion batteries



Ultranode™


AnteoTech's **Ultra High Silicon Anode** is a **proprietary high silicon anode** offering increased energy capacity, faster charging and low cost



Life Sciences

AnteoBind™ & AnteoBind NXT™

AnteoTech's **unique products** that offer significant productivity benefits in the manufacture of diagnostic products



Development Services

SILICON: THE FUTURE OF BATTERY ANODES


The shift to silicon anodes provides a **technological performance improvement** which can accelerate the clean energy transition.

Silicon a technological leap

- **Performance:** Up to 35% increase in energy density
- **Cost reduction:** 8.5x cheaper per kWh potential
- **Sustainability:** Reduces battery size and material usage
- **Utilisation of** existing manufacturing infrastructure

Strategic Supply Chain Advantages

- **Silicon is Plentiful** – Silicon is **widely available** and can be sourced locally unlike graphite (>70% silicon from China).
- **Reduced Supply Chain Risk** – Diversifies raw material sourcing and **lowers geopolitical exposure** in battery manufacturing.
- **Scalability & Cost Reduction** – Advancements in **silicon processing** are making it more cost-effective for mass production.




SILICON THE SOLUTION TO RANGE ANXIETY

Ultranode™ uses a silicon-based anode to store more energy in the same volume compared to traditional graphite, leading to **longer range** and potential for **faster charging**.

- >70% silicon active material
- Demonstrated 900 cycles at 70% capacity retention
- Roadmap to >1,000 cycles
- Use of lowest cost readily available silicon



Ultranode™ harnesses readily available silicon to revolutionise battery technology with enhanced performance and sustainability.



EVs TODAY

0-10%
Silicon content

450km¹
Driving
range

Cell 626 Wh/l⁴

Standard Battery Pack³




AnteoTech Ultranode Target

>70%
Silicon content

+144Km
594 km²
Driving
range

Cell 826 Wh/l²

32%↑ in Wh per cell volume³



1. Tesla Model Y - <https://ev-database.org/car/3104/Tesla-Model-Y-Long-Range-AWD>

2. Internal modelling based on targeted Ultranode capacity and Tesla Model Y data. Values subject to change based on cell form factors and cell component choices. 3. Battery Pack Illustrative only

4. <https://www.batemo.com/products/batemo-cell-explorer/unknown-manufacturer-tesla-model-y-4680/>

CLEAN ENERGY – NEAR-TERM OPPORTUNITIES

Key targets to building revenue for Anteo X™ and Ultranode™




Electric Vehicles

Mercedes-Benz

- Support ongoing evaluation of Anteo X™ and Ultranode™
- Ultranode™ agreement– Target 2H25
- Target Anteo X™ sales for next gen. batteries

EV2 & EV3

- Ongoing discussions as they focus on next generation battery developments with high performance and lowest delivered cost per kW/h



Advanced Chemistries

Separator Technology

- Confirmation that Anteo X™ reduces shrinkage > safer batteries
- Optimisation of formulation
- Target commercial agreement for Anteo X™

Carbon Nano Tubes

- Confirmation Anteo X™ delivers expected performance improvements
- Partner validation then targeting commercial agreement to develop enhanced products with Anteo X™



Consumer & Medical

Wyon

- Leverage recent visit and move to high silicon anode sales.

Consumer Battery

- Target Commercial agreement in US for mobile phone batteries
- Development agreement with niche high performance battery company
- Leverage Intl Sales Directors relationships across the industry

LIFE SCIENCES – TARGETING INDIAN GROWTH OPPORTUNITIES

Building revenue streams for AnteoBind and AnteoBind NXT



US\$1.8m min. Purchase Agreement – 5 years

- Continue to expand usage in current vaccine program QA
- Expand into new vaccine development programs
- Expand relationship through assay development services
- Explore growth in SII-Lateral flow and other diagnostic tests



Business Development Targets – Vidcare

- Management meeting planned in India in 2HFY25
- Completing validation of AnteoBind NXT in the initial PoC test for India
- Proprietary in-home test for diagnosis of hypothyroidism (or underactive thyroid)



Indian market expansion

Evaluation underway

- Targeted strategy for multiple Indian PoC companies
- Rapidly expanding healthcare sector with increasing demand for advanced diagnostic solutions
- Leverage Indian government “Health for All” initiatives
- Validation of AnteoBind NXT underway with several India companies

CORPORATE SNAPSHOT

Balance Sheet strengthened with new institutional shareholders joining the share register in 2024.

Market Capitalisation¹

\$46m

Cash²

\$7.4m

Debt

Nil



Capital Structure

Shares (ADO)	2,705 million
Options (ADOO)	148 million
Unlisted Options	197 million
Institutions	~6.6%
Board & Mgmt	1.5% + Options

¹ Closing share price on 5 February 2025

² As at 30 December 2024

FIVE KEY TAKEAWAYS

Addressing global challenges, supporting the transition to renewable energy and democratising healthcare in growing markets.

1

Near term revenue opportunities in targeted market segments.

Opportunities across Clean Energy Technology and Life Science divisions

2

Next generation battery products – validated by external partners

Two evaluations with Mercedes on track with path to potential development agreement – evaluations with other leading companies across battery sector

3

Clean energy revenues – platform for sales and growth

Production Facility & Technical team in place to support near term customer requirements

4

Expanding usage of AnteoBind™ – world's largest vaccine manufacturer

Expanding usage building long term revenues

5

Multiple commercial milestones in 2025

Agreements - Sales of products – Paid development activities – Partnering opportunities

David Radford

CEO & Managing Director

investors@anteotech.com

Thank you.

